Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/gut.2009.194100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inflammatory biomarker analysis confirms reduced disease severity in heterozygous patients with familial Mediterranean fever.
RMD Open
November 2024
Pediatric Rheumatology and Immunology, University Medicine, Albert-Schweitzer-Campus 1, Munster, Germany.
Article Synopsis
- Familial Mediterranean fever (FMF) is a genetic condition marked by inflammation episodes, usually treated with colchicine to prevent complications like amyloid A amyloidosis, but its necessity for heterozygous patients is debated.* -
- A study analyzed 747 FMF patients' demographic and inflammatory biomarker data, revealing that heterozygous patients generally exhibited lower inflammatory markers compared to those with more severe genetic variants.* -
- The findings suggest that certain biomarkers (S100A8/A9 and S100A12) can indicate disease activity, and some heterozygous patients may be eligible to safely stop colchicine treatment.*
Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis.
Arthritis Res Ther
November 2024
Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Building 10, CRC Rm 6-5700, MSC 1301 10 Center Drive, Bethesda, MD, 20892-1301, USA.
Article Synopsis
- The study aimed to identify differences in serum protein levels between adult and juvenile dermatomyositis (DM and JDM) patients compared to healthy controls to find potential biomarkers for disease activity.
- A multiplex immunoassay was used to analyze serum protein expression from 17 active DM and JDM patients, revealing 78 out of 172 proteins were differentially expressed, with specific proteins highlighted for each patient group.
- The analysis showed activated signaling pathways in both DM and JDM, with several proteins correlating with disease activity, suggesting potential candidates for monitoring the condition's severity.
Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.
Front Cardiovasc Med
October 2024
Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Background: Sepsis is characterized by high morbidity and mortality rates, alongside limited therapeutic efficacy. Atrial fibrillation (AF), the most common arrhythmia, has been closely linked to sepsis in prior research. However, the specific mechanisms through which sepsis leads to new-onset AF remain poorly understood.
View Article and Find Full Text PDFThe levels of amino acid metabolites in serum induce the pathogenesis of atopic dermatitis by mediating the inflammatory protein S100A12.
Sci Rep
October 2024
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Article Synopsis
- Atopic dermatitis (AD) is a widespread chronic skin condition, but the link between metabolites and its development hasn't been fully understood yet.
- * This study investigates the genetic connections between metabolites and AD, focusing on how amino acid metabolites like N6-methyllysine influence the disease through the inflammatory protein S100A12.
- * Results showed that S100A12 is associated with various immune cells in AD-affected skin and is a key mediator between certain metabolites and the onset of AD.
Recent advances in proteomic analysis to study carotid artery plaques.
JVS Vasc Sci
August 2024
Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, FL.
Objective: We sought to identify differentially expressed proteins in serum, plasma, and plaque samples of patients with carotid atherosclerotic lesions.
Methods: We performed a systematic review of the proteomic profile of serum, plasma, and plaque samples of patients with carotid artery disease. We included full-length peer-reviewed studies of adult humans and reported them using PRISMA guidelines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!